Affordable Access

Chemotherapies and immunotherapies for metastatic kidney cancer.

Authors
Type
Published Article
Journal
Current urology reports
Publication Date
Volume
6
Issue
1
Pages
35–42
Identifiers
PMID: 15610695
Source
Medline
License
Unknown

Abstract

Most patients who develop kidney cancer are effectively treated with a radical nephrectomy; however, for those patients who present with or develop metastatic disease, the therapeutic options are limited. Interferon and interleukin-2 remain the standard therapies. Several studies have identified the optimal doses and schedules of these cytokines and groups of patients most likely to benefit from immunotherapy. Although cytotoxic chemotherapy continues to have a minor role in patients with clear cell renal carcinoma, it may become the treatment of choice for some patients with variant renal cancers. Novel agents targeting the vascular endothelial growth factor, its receptor, and other hypoxia-induced proteins are showing great promise and soon may expand the therapeutic options for patients with advanced kidney cancer.

Statistics

Seen <100 times